MNOV Valuation

MediciNova Inc

Add to Watchlist

Advanced Chart

1.380

+0.110(+8.660%)

Overview
Forecast
Valuation

MNOV Relative Valuation

MNOV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MNOV is overvalued; if below, it's undervalued.

Historical Valuation

MediciNova Inc (MNOV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 48.37. The fair price of MediciNova Inc (MNOV) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.38

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.29

P/B

Median3y

1.47

Median5y

1.96

-17.09

FCF Yield

Median3y

-11.20

Median5y

-8.65

Competitors Valuation Multiple

The average P/S ratio for MNOV's competitors is 0.34, providing a benchmark for relative valuation. MediciNova Inc Corp (MNOV) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap